7. An isolated antibody, wherein the antibody specifically binds ApoE and comprises a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:33 with zero to two amino acid substitutions.

8. ~~A method of treating at least one symptom or sign of Aß plaque associated symptoms in a subject which comprises administering an effective amount~~Use of at least one anti-ApoE antibody in the manufacture of a medicament for treating at least one symptom or sign of Aß plaque associated symptoms in a subject ~~to that subject~~.

9. The use~~method~~ of claim 8, wherein the treating includes preventing, attenuating, reversing, or improving at least one symptom or sign of Aß plaque associated symptoms in a subject.

10. The use~~method~~ of claim 8, wherein a symptom or sign of Aß plaque associated symptoms includes impaired cognitive function, altered behavior, abnormal language function, emotional dysregulation, seizures, impaired nervous system structure or function, and an increased risk of development of Alzheimer's disease or cerebral amyloid angiopathy.

11. The use~~method~~ of claim 8, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

12. The use~~method~~ of claim 8, wherein the administration comprises an effective systemic route of administration.

13. The use~~method~~ of claim 8, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

14. ~~A method of decreasing the amyloid plaque load in the brain of a subject, the method comprising administering an effective amount~~Use of at least one anti-ApoE antibody in the manufacture of a medicament for decreasing the amyloid plaque load in the brain of a subject~~to that subject~~.

15. The use~~method~~ of claim 14, wherein the anti-ApoE antibody binds an epitope within the ApoE coding sequence.

16. The use~~method~~ of claim 14, wherein the administration comprises an effective systemic route of administration.

17. The use~~method~~ of claim 14, wherein the administration comprises an effective local route of administration including directly within the central nervous system.

18. The use~~method~~ of claim 14, wherein the amyloid plaque loads are decreased in the hippocampus.

19. The use~~method~~ of claim 14, wherein the amyloid plaque loads are decreased in the cortex.